IP Library Granted Patent US 10,960,027
Granted Patent B2
US 10,960,027 · App. 16/087,358 · Granted Mar 30, 2021

Compositions and methods of treatment with amniotic fluid

Inventors: Thomas J. Koob (Marietta, GA); Michelle Massee (Marietta, GA)
Assignee: MiMedx Group, Inc.
A61K35/50A61K9/0014A61K9/0019A61K9/0078A61K9/06A61K9/19A61K47/34A61K47/36A61K47/42A61K47/46A61M5/31A61M11/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,960,027
App. No.
16/087,358
Granted
Mar 30, 2021
Kind
B2
Abstract

The present disclosure provides compositions composed of amniotic fluid and/or modified amniotic fluid, a pharmaceutically acceptable carrier, and optionally a placental tissue graft, micronized placental tissue components, or extracts derived therefrom. Also described are systems and apparatuses for administering or storing said compositions, as well as methods of treatment using said compositions.

Claims (29)

1. A composition comprising an amount of modified amniotic fluid wherein said amniotic fluid is sterilized and desalted;

wherein the modified amniotic fluid has been desalted to remove all or substantially all salts; or

wherein the modified amniotic fluid has a salt concentration of 0.9% saline +/−0.1%.

2. The composition of claim 1 , wherein the modified amniotic fluid is free or substantially free of material greater than 1 μm in size.

3. The composition of claim 1 , wherein the modified amniotic fluid is human amniotic fluid.

4. The composition of claim 1 , wherein the modified amniotic fluid is free or substantially free of cells and/or cellular debris.

5. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.

6. The composition of claim 5 , wherein the modified amniotic fluid and pharmaceutically acceptable carrier have a weight ratio in the range between 1:10 and 10:1.

7. The composition of claim 5 , wherein the pharmaceutically acceptable carrier is Wharton's jelly, a biocompatible gelation agent, a polysaccharide, hyaluronic acid, poly-1-lysine, or collagen.

8. The composition of claim 1 , wherein the composition is injectable; is a topical composition; or is a liquid, gel, or paste.

9. The composition of claim 1 , wherein the composition is a sprayable composition.

10. A solid pellet comprising a dried droplet of the composition of claim 1 .

11. A molded composition comprising an amount of the composition of claim 1 dried in a mold.

12. A composition comprising an amount of the composition of claim 1 and a placental tissue graft.

13. A composition comprising an amount of the composition of claim 1 and an amount of micronized placental tissue particles.

14. A method for treating a gastrointestinal disease or disorder, a skin disease or disorder, a pulmonary disease or disorder, the method comprising administering to a patient in need thereof an amount of a composition comprising an amount of modified amniotic fluid wherein said amniotic fluid is sterilized and desalted;

wherein the modified amniotic fluid has been desalted to remove all or substantially all salts; or

wherein the modified amniotic fluid has a salt concentration of 0.9% saline +/−0.1%.

15. A method for treating a patient who has undergone a cosmetic procedure, the method comprising administering to the patient an effective amount of a composition comprising an amount of modified amniotic fluid wherein said amniotic fluid is sterilized and desalted;

wherein the modified amniotic fluid has been desalted to remove all or substantially all salts; or

wherein the modified amniotic fluid has a salt concentration of 0.9% saline +/−0.1%.

16. A method for preventing or reducing scar formation on the spine or near the spine, or sealing a dural tear, or for treating or preventing an anterior procedure or a modified anterior procedure, the method comprising administering to a patient in need thereof an effective amount of a composition comprising an amount of modified amniotic fluid wherein said amniotic fluid is sterilized and desalted;

wherein the modified amniotic fluid has been desalted to remove all or substantially all salts; or

wherein the modified amniotic fluid has a salt concentration of 0.9% saline +/−0.1%.

17. A method for enhancing wound healing or preventing scar formation as a result of a surgical incision, or for reducing the amount of scar tissue in a reproductive system after a surgical procedure, the method comprising administering to a patient in need thereof an effective amount of a composition comprising an amount of modified amniotic fluid wherein said amniotic fluid is sterilized and desalted;

wherein the modified amniotic fluid has been desalted to remove all or substantially all salts; or

wherein the modified amniotic fluid has a salt concentration of 0.9% saline +/−0.1%.

18. The composition of claim 1 , wherein the modified amniotic fluid has been desalted to remove all or substantially all salts.

19. The composition of claim 1 , wherein the modified amniotic fluid has a salt concentration of 0.9% saline +/−0.1%.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Feb 5, 2024
From: HAYFIN SERVICES LLP
To: MIMEDX GROUP, INC.; MIMEDX PROCESSING SERVICES, LLC
Reel/Frame 066493/0322 →
SECURITY INTEREST Recorded Jan 25, 2024
From: MIMEDX GROUP, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 066371/0136 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2020
From: KOOB, THOMAS J.; MASSEE, MICHELLE
To: MIMEDX GROUP, INC.
Reel/Frame 054267/0622 →
PATENT SECURITY AGREEMENT Recorded Jul 2, 2020
From: MIMEDX GROUP, INC.; MIMEDX PROCESSING SERVICES, LLC
To: HAYFIN SERVICES LLP, AS COLLATERAL AGENT
Reel/Frame 053121/0833 →
RELEASE OF SECURITY INTEREST Recorded Jul 2, 2020
From: BLUE TORCH FINANCE LLC, AS COLLATERAL AGENT
To: MIMEDX GROUP, INC.; MIMEDX PROCESSING SERVICES, LLC
Reel/Frame 054075/0687 →
SECURITY INTEREST Recorded Jun 11, 2019
From: MIMEDX GROUP, INC.
To: BLUE TORCH FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 049426/0863 →
Continuity (4)
Provisional Application 62312403 · Mar 23, 2016
Provisional Application 62312379 · Mar 23, 2016
Provisional Application 62312391 · Mar 23, 2016
Related Publication 20200129562A1 · Apr 30, 2020